A phase I study of AIM ACT for patients with high risk AML who have relapsed after an allogeneic hematopoietic stem cell transplant (HSCT).

Trial Profile

A phase I study of AIM ACT for patients with high risk AML who have relapsed after an allogeneic hematopoietic stem cell transplant (HSCT).

Planning
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs AIM ACT (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Oct 2017 New trial record
    • 17 Oct 2017 According to a NexImmune media release, the Company has completed Pre-IND discussions with the FDA, and expects to submit an IND in 1HQ2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top